)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sumitomo Pharma
Sumitomo Pharma (4506) investor relations material
Sumitomo Pharma Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary30 Oct, 2026
Executive summary
H1 FY2027 revenue rose 17.3% YoY to ¥266.5bn; core operating profit fell 56.2% to ¥42.1bn and net profit fell 61.3% to ¥38.2bn.
U.S. ORGOVYX and GEMTESA growth drove revenue gains; higher commercial and R&D spending, mix effects and the absence of prior-year gains weighed on profit.
FY2027 revenue guidance rose to ¥565bn, with core operating profit of ¥105bn; a ¥15/share year-end dividend is planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sumitomo Pharma
- Revenue up 19.9% and net profit up 51.7% YoY, led by U.S. sales and FX gains.4506
Q1 2027 - FY2025 saw record profit and U.S. growth; FY2026 targets revenue gains but lower profit.4506Q4 2026
- Accelerating growth with strong product sales, pipeline innovation, and disciplined financial management.4506Investor presentation
- Core operating profit surged 408.5% on strong North America growth and Asian business gains.4506Q3 2026
- Profit and revenue rebounded on strong North America sales and China-Asia business transfer gains.4506Q2 2026
- Revenue up 19.1% year-over-year, led by ORGOVYX and GEMTESA; net profit down on FX losses.4506Q1 2026
- Revenue up 18.4%, losses narrowed, and liquidity improved on asset sales and restructuring.4506Q2 2025
- Profit rebounded on U.S. sales and cost cuts; FY2025 profit to rise despite lower revenue.4506Q4 2025
- Profitability restored and outlook raised on strong U.S. sales and cost controls.4506Q3 2025
Next Sumitomo Pharma earnings date
Q3 202729 Jan, 2027
Sumitomo Pharma
Next Sumitomo Pharma earnings date
Q3 202729 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs and medical solutions. The company focuses on therapeutic areas such as psychiatry, neurology, oncology, and infectious diseases. The company is headquartered in Osaka, Japan, and its shares are listed on the Tokyo Stock Exchange (TSE).